Diaboline | 509-40-0

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 马钱子生物碱
• 英文名称: Diaboline
• 英文别名: 1-[(4R,19R,21S)-14-hydroxy-15-oxa-1,11-diazahexacyclo[16.3.1.04,12.04,21.05,10.013,19]docosa-5,7,9,17-tetraen-11-yl]ethanone
• CAS: 509-40-0；906-68-3；21141-18-4；64783-88-6
• 化学式: C₂₁H₂₄N₂O₃
• 分子量: 352.433
• InChiKey: QSDMAJZSSDNJPO-DTHZKQTCSA-N

物化性质

• 熔点：
  187°
• 比旋光度：
  D22 +37.8° (c = 1.72 in chloroform)
• 沸点：
  624.1±55.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  26
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  53
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT
  申请人：Bioniqs Limited

  公开号：EP2001877A1

  公开（公告）日：2008-12-17
• WO1989005301A1
  申请人：——

  公开号：WO1989005301A1

  公开（公告）日：1989-06-15
• [EN] METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT<br/>[FR] PROCÉDÉ D'EXTRACTION D'UN ALCALOÏDE CIBLE FAISANT APPEL À UN LIQUIDE IONIQUE COMME SOLVANT D'EXTRACTION
  申请人：BIONIQS LTD

  公开号：WO2007110637A1

  公开（公告）日：2007-10-04

  [EN] Method for extracting a target alkaloid from a mixture of species, typically from plant matter, using an ionic liquid as an extracting solvent. The ionic liquid may in particular be an alkanolyl-, alkoxyalkyl- or aminoalkyl-substituted ammonium salt.
  [FR] L'invention concerne un procédé d'extraction d'un alcaloïde cible à partir d'un mélange d'espèces, généralement d'un matériau végétal, en utilisant un liquide ionique en tant que solvant d'extraction. Le liquide ionique peut notamment être un sel d'ammonium substitué par un alcanoyle, un alcoxyalkyle ou un aminoalkyle.
• [EN] TREATING NEUROMUSCULAR OR NEUROLOGIC DISEASE THROUGH REDUCING GABAERGIC AND/OR GLYCINERGIC INHIBITORY NEUROTRANSMITTER OVERSTIMULATION<br/>[FR] TRAITEMENT DE MALADIE NEUROMUSCULAIRE OU NEUROLOGIQUE PAR RÉDUCTION DE LA SURSTIMULATION DES NEUROTRANSMETTEURS INHIBITEURS GABAERGIQUES ET/OU GLYCINERGIQUE
  申请人：RY PHARMA B V

  公开号：WO2016114655A1

  公开（公告）日：2016-07-21

  The disclosure provides novel methods of treating neuromuscular or neurologic disease, for example, Amyotrophic lateral sclerosis (ALS), through reducing GABAergic and Glycinergic inhibitory neurotransmitter activity overstimulation. Pharmaceutical compositions comprising one or more compounds capable of reducing Glycinergic activity and/or one or more compounds capable of reducing GABAergic activity are also provided. Methods for treating one or more symptoms caused by inhibitory neurotransmitter overstimulation (e.g., muscle wasting, loss of muscle function, loss of muscle coordination, respiratory depression, dysphagia, dysarthria, eye movement difficulties, oculomotor gaze palsy, supranuclear gaze palsy, bladder dysfunction and gastrointestinal dysfunction) in an individual afflicted with ALS or an ALS- like disorder are also provided.
• [EN] TREATING NEUROMUSCULAR OR NEUROLOGIC DISEASE THROUGH REDUCING GABAERGIC AND/OR GLYCINERGIC INHIBITORY NEUROTRANSMITTER OVERSTIMULATION<br/>[FR] TRAITEMENT DE MALADIE NEUROMUSCULAIRE OU NEUROLOGIQUE PAR RÉDUCTION DE LA SURSTIMULATION DES NEUROTRANSMETTEURS INHIBITEURS GABAERGIQUES ET/OU GLYCINERGIQUES
  申请人：RY PHARMA B V

  公开号：WO2017065602A1

  公开（公告）日：2017-04-20

  The disclosure provides novel methods of treating neuromuscular or neurologic disease, for example, Amyotrophic lateral sclerosis (ALS), through reducing GABAergic and Glycinergic inhibitory neurotransmitter activity overstimulation. Pharmaceutical compositions comprising one or more compounds capable of reducing Glycinergic activity and/or one or more compounds capable of reducing GABAergic activity are also provided. Pharmaceutical compositions comprising Penicillin G and, optionally, glucocorticoid are especially useful in the present invention. Methods for treating one or more symptoms caused by inhibitory neurotransmitter overstimulation (e.g., muscle wasting, loss of muscle function, loss of muscle coordination, respiratory depression, dysphagia, dysarthria, eye movement difficulties, oculomotor gaze palsy, supranuclear gaze palsy, bladder dysfunction and gastrointestinal dysfunction) in an individual afflicted with ALS or an ALS- like disorder are also provided.